Unternehmen wird geladen
Just reported
Q3 2026 results
From Teleflex's results release of 5. November 2026; its quarterly report has since been filed.
Revenue
Actual
567,8M $
+0,1 % y/y
-0,4 % q/qGuided
—
No guide given
EPS, GAAP
Actual
22,28 $
Guided
—
No guide given
Operating income, GAAP
Actual
105,4M $
+45 % q/q
Guided
—
No guide given
Company outlook
Full year 2026
- EPS, adjusted7,50 $ – 7,75 $Raised +8,2 %
- EPS, GAAP2,84 $ – 3,09 $Raised +10 %
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Teleflex is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Medical Instruments and Supplies
Graded A or B and worth $2B or more: A first, then the largest.
ISRGIntuitive Surgical, Inc.152,5B $A+
MDLNMedline Inc.52,6B $A
ALCAlcon Inc.35B $A
BLCOBausch & Lomb Corp7,6B $A-
ATRCAtriCure, Inc.2,9B $A
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21. Okt. 2026CBGraded C, now B
MCKMckesson Corporation4. Nov. 2026BAGraded B, now A
CVSCVS Health Corp4. Nov. 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4. Nov. 2026BAGraded B, now A
BIIBBiogen Inc.28. Okt. 2026BAGraded B, now A
Gebaut aus den eigenen Einreichungen von Teleflex Incorporated bei der US-Börsenaufsicht Securities and Exchange Commission (SEC). Die Zahlen sind wie berichtet, die Historie je Aktie auf die heutige Aktienbasis umgerechnet. Dies beschreibt ein Unternehmen — es ist keine Anlageberatung und keine Kauf- oder Verkaufsempfehlung.
